Part 5: Science, Research and Technology (Feb. 2005)

[2/28/2005] CDRI Expects Herb-Based Anti-TB Product
According to an article on Express India, India's Central Drug Research Institute (CDRI) is hoping to bring an herb based anti-tuberculosis product to the market in the next two years.
Internet Resources:

[2/28/2005] Study Results Show Efficacy of Bioforce’s Prostasan
US-based Bioforce has noted results of an eight week Swiss study on 364 men from last year, which indicated that taking 320 mg of Prostasan saw palmetto extract reduced the severity of benign prostatic hyperplasia (BPH) symptoms with symptom reduction ranging from 42% in cases of mild BPH, to 30% reduction in cases of severe BPH.
Internet Resources:

[2/28/2005] Parthenolide Induces Apoptosis of Leukemia Stem and Progenitor Cells
According to research at the University of Rochester Medical School, published in the February issue of the journal 'Blood', parthenolide, a compound found in feverfew, induces apoptosis in leukemia stem cells while sparing normal cells. According to the researchers, parthenolide was also compared to cytarbine, a chemotherapy drug used for leukemia, which showed 'modest toxicity' to leukemia cells and 'relatively high toxicity' to normal cells.
Internet Resources:

[2/25/2005] Poor Prenatal Nutrition Permanently Damages Function of Insulin-producing Cells in the Pancreas
Research funded by the American Diabetes Association and the Adler Foundation and conducted by the Joslin Diabetes Center, has indicated, through mice studies, that poor prenatal nutrition impairs the pancreas's ability to later secrete enough insulin in response to blood glucose, leading to elevated risk of Type 2 diabetes later in life.
Internet Resources:

[2/21/2005] Advitech and CHUL Research Center to Test XP-828L
Canada-based biotech company Advitech and the CHUL Research Center, CHULRC (CHUQ)will initiate a research project to examine the potential of XP-828L, a purified milk protein fraction with a patented growth factor composition, for the treatment of inflammatory bowel diseases.
Internet Resources:

[2/21/2005] Tate & Lyle to Launch New Venture Fund
According to an article on, UK-based sweetener company Tate & Lyle PLC has announced the formation of Tate & Lyle Ventures, a fund that will invest in next-generation food and industrial ingredients. According to the article, the initial investment was £25 million (US$47.4 million) over five years.
Internet Resources:

[2/18/2005] Rats Fed With Organic Produce Seem to Be Healthier
According to a Yahoo News article citing AFP as the source, researchers at the Danish Institute of Agricultural Sciences have determined that rats fed organic produce had more vitamin E as well as less body fat than those raised on non-organic food.
Internet Resources:

[2/16/2005] New Chromium Supplementation Clinical Trial Initiated
Nutrition 21, Inc. (NASDAQ: NXXI) has announced the initiation of the first double-blind, randomized, placebo-controlled clinical trial to study the effects of chromium picolinate supplementation in overweight pediatric patients with poorly-controlled type 1 diabetes. According to the company, the trial will be conducted at Children’s Hospital Los Angeles, and will see the addition of 600mcg of chromium picolinate to the diets of patients aged 12 to 18.
Internet Resources:

[2/15/2005] Researchers Find New Health Benefits for Mushrooms
According to an article on, researchers at University of Illinois at Urbana-Champaign have found that six varieties of mushrooms they tested were high in total dietary fibres, including chitin and beta-glucan. The research was funded by the Mushroom Council of Dublin, California.
Internet Resources:

[2/14/2005] Nutrient Combination Effective Against Chemically Induced Breast Cancers
Research on an in vivo rat model, published in Breast Cancer Research (Breast Cancer Research 2005, 7:R291-R295) indicates that a nutrient combination, developed by Dr. Matthias Rath, and containing a combination of lysine, proline, arginine, ascorbic acid, and green tea extract (nutrient synergy), was effective in reducing the incidence of N-methyl-N-nitrosourea-induced mammary tumors by 68.4% with a reduction in total tumor burden. According to the release issued by the Dr. Rath Institute, "all tumors developed in the control animals were malignant adenocarcinomas, whereas tumors developed in the animals supplemented with nutrient synergy were non-malignant adenomas."
Internet Resources:

[2/11/2005] Study

Compares St.
John's Wort and Antidepressant Drug
Research from Germany, published in the online version of the British Medical Journal, has compared the effect of St. John's wort with the GlaxoSmithKline (GSK) antidepressant drug Paxil or Seroxat. According to an article on, researchers noted that half of those given St. John's wort for six weeks reported an improvement in their symptoms, versus one third of those who took Seroxat. The group taking Seroxat also reported more side effects, consistent with the results of an investigation by the Medicines and Healthcare Regulatory Authority last year, which concluded that the drug should be avoided in cases of mild depressions, due to its side effects. In an article on iWon, a spokesperson from GSK noted that the study had drawn its conclusions from a single clinical trial of 251 outpatients, and commented on the interaction between St. John's wort and various drug products, reducing or altering the effectiveness of these medications. An article on notes that the herbal extract used in the study was WS5570, made by Dr Willmar Schwabe Pharmaceuticals, the company which funded the trial. A press release issued by Schwabe notes that the St. John's wort group received 900 mg/day of WS(R) 5570, and the other 20 mg/day of paroxetine.
Internet Resources:§ion=news&news_id=dji-00050120050211&date=20050211&alias=/alias/money/cm/nw

[2/11/2005] U.S. Department of Defense University and Humanetics to Co-Develop Multiple Compounds
Humanetics Corporation, the Uniformed Services University of the Health Sciences (USU), and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) have initiated an agreement to develop and commercialize nutritional supplements and drugs that show promise in supporting and protecting the immune system against challenges from exposure to radiation. According to the release issued by Humanetics, the company will sponsor a research program with the Armed Forces Radiobiology Research Institute (AFRRI), and the F. Edward Ebert School of Medicine.
Internet Resources:

[2/8/2005] Study Shows Green Tea Boosts Exercise Endurance
According to a study published in the online edition of American Journal of Physiology, Regulatory, Integrative and Comparative Physiology, researchers at Japan's Kao Corp. have tested the effects of regular consumption of green tea extract in mice, finding that over ten weeks, endurance exercise performance rose 24% and 8% with 0.5% and 0.2% extract supplementation respectively. According to the article, the researchers noted that a single dose of either green tea extract or green tea ingredients did not affect performance.
Internet Resources:

[2/4/2005] Diets Rich in Rice Bran Oil May Lower Cholesterol
According to an article on, two small studies reported in the American Journal of Clinical Nutrition suggest that rice bran oil lowered cholesterol levels in individuals with moderately high cholesterol. In one study, the researchers found that adding rice bran lowered cholesterol as effectively as did an oat-bran containing diet, and in the other study, 14 participants followed two different diets for five weeks, with participants changing a portion of their diet from a blend of peanut oil, olive oil, corn oil, canola oil, palm oil and butter to rice bran oil in the second five week period. The researchers noted that cholesterol levels were lowest when the diet consisted of rice bran oil.
Internet Resources:

[2/3/2005] BASF Venture Capital Invests in Novel Encapsulation Technology
Germany-based BASF Venture Capital GmbH has announced a €2 million investment in Germany-based Cavis Microcaps GmbH. Cavis has developed a technology and production process that uses small capsules to protect sensitive substances - for example yeasts, probiotics (health-promoting bacteria), vitamins or enzymes - from degradation.
Internet Resources:

[2/3/2005] KGK Synergize Purchases LC/MS/MS
Canada-based contract research company KGK Synergize has announced the purchase of a Varian Model #1200L LC/MS/MS , which, according to the company, will be used to expand analytical capabilities to include the identification and quantification of drugs, polysaccharides, peptides, proteins, vitamins, steroids, pesticides and toxins.
Internet Resources:

[2/2/2005] Folic Acid Benefits Reduced in Obese Mothers
According to a Reuters Health article on Yahoo News, researchers from the University of Toronto, in a study published in the February issue of Obstetrics & Gynecology, have noted that while increasing a mother's intake of folic acid by adding it to food supplies has been shown to cut the risk of having a baby with neural tube defects, the benefit is weaker in overweight or obese women. According to the article, which examined the effects of Canada's folic acid fortification program introduced in 1997, in the heaviest women, the program cut the risk of neural tube defects by 40%, while in lighter women, the risk was reduced by up to 90%.
Internet Resources:

[2/2/2005] Yakult to Establish European Research Centre
According to a report on, Japan-based drink manufacturer Yakult Honsha has indicated it plans to build an overseas research center to be located in Ghent, Belgium, where researchers will study the intestinal microbial flora of Europeans.
Internet Resources:

[2/1/2005] Calcium and vitamin D treatment alone can improve bone mineral density in Crohn's patients
According to research published in the American Gastroenterological Association (AGA) journal Clinical Gastroenterology and Hepatology, indicates that calcium and vitamin D treatment alone can improve bone mineral density in patients with Crohn's disease by 3 to 4% per year, and the addition of bone building drugs to the regimen provides no further benefit.
Internet Resources:

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.